Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

Bilici, AhmetOlmez, Omer FatihSezer, AhmetOksuzoglu, BernaKaplan, Muhammet AliKaradurmus, NuriCubukcu, Erdem2024-04-242024-04-2420220732-183X1527-7755https://hdl.handle.net/11468/23147Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 03-07, 2022 -- ELECTR NETWORK[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keyword]Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).Conference Object4016WOS:000863680302513Q1